Atul Deodhar

1 month ago | healio.com | Justin Cooper |Shenaz Bagha |Atul Deodhar

Key takeaways: There were no new safety signals, while all fungal infections were mild-to-moderate and non-systemic. Efficacy was persistent even with non-responder imputation. A 5-year study of bimekizumab in ankylosing spondylitis encountered no new safety signals, with efficacy sustained even in a conservative analysis with non-responder imputation, according to data published in RMD Open.

Nov 1, 2024 | acrjournals.onlinelibrary.wiley.com | Atul Deodhar |Jerzy Supronik |Alan Kivitz |Guillermo Valenzuela

INTRODUCTION Axial spondyloarthritis (axSpA) is a chronic immune-mediated disease marked by axial skeletal inflammation and subsequent pain, stiffness, functional impairment, and reduced quality of life.1 AxSpA disease manifestations exist on a spectrum including radiographic (r)-axSpA and nonradiographic (nr)-axSpA, characterized by the presence or absence of definitive radiographic damage to the sacroiliac joints, respectively.2-5 Biologic treatments, including tumor necrosis factor...

Sep 20, 2024 | acrjournals.onlinelibrary.wiley.com | Atul Deodhar |Jerzy Supronik |Alan Kivitz |Guillermo Valenzuela

INTRODUCTION Axial spondyloarthritis (axSpA) is a chronic immune-mediated disease marked by axial skeletal inflammation and subsequent pain, stiffness, functional impairment, and reduced quality of life.1 AxSpA disease manifestations exist on a spectrum including radiographic (r)-axSpA and nonradiographic (nr)-axSpA, characterized by the presence or absence of definitive radiographic damage to the sacroiliac joints, respectively.2-5 Biologic treatments, including tumor necrosis factor...

Mar 25, 2024 | mdedge.com | Atul Deodhar

Over the past two decades, the therapeutic landscape for psoriatic arthritis (PsA) has been transformed by the introduction of more than a dozen targeted therapies. For most patients with active PsA, a tumor necrosis factor (TNF) inhibitor is recommended as the first-line biologic therapy. But some patients do not achieve an adequate response to TNF inhibitors or are intolerant to these therapies.

Oct 4, 2023 | ard.bmj.com | Xenofon Baraliakos |Atul Deodhar |Marina N. Magrey |Walter P. Maksymowych

Safety data for the DBTP have been reported previously and are summarised in table 3.22 At Week 52, ≥1 TEAE was reported for 183 out of 244 (75.0%; EAIR/100 PY: 202.1) patients with nr-axSpA and 249 out of 330 (75.5%; EAIR/100 PY: 200.8) with r-axSpA who had received ≥1 dose of BKZ (table 3).